AzTrials
AzTrials

DyspneaPhase 2BIS-PhIInmNCT00711438

Pilot Randomized Controlled Trial of a Breathlessness Intervention Service for Chronic Obstructive Pulmonary Disease

A Phase 2 study testing Breathlessness Intervention Service (BIS) in people with Dyspnea, run by Cambridge University Hospitals NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to test the feasibility of conducting a pragmatic fast track Randomized Controlled Trial (RCT) of the Breathlessness Intervention Service (BIS) versus standard care for patients with COPD and their carers, and to begin testing the effectiveness of the intervention. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Dyspnea
What is being tested?
Breathlessness Intervention Service (BIS)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13 participants
Where
1 siteUnited Kingdom
Study dates
Apr 2006to Apr 2007
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients:
  • Appropriate referral to the BIS
  • Diagnosis of COPD/COAD
  • Aged 18 years or over
  • Any patient who does not meet any of the exclusion criteria
  • Carers:
Show all 9Show fewer
  • The informal carers of patients specified above, who can be significant others, relatives, friends or neighbours
  • Aged 18 years or over
  • Any carer who does not meet the exclusion criteria

Who cannot join

  • Any patient/carer unable to give informed consent
  • Any patient living outside of Cambridgeshire PCT, West Essex PCT, East \& North Hertfordshire PCT, or Suffolk PCT
  • Any patient who has previously had access to BIS
  • Any patient/carer who is demented or confused
  • Any patient/carer with learning difficulties
  • Any patient/carer from other vulnerable groups (e.g. head injury, severe trauma, and mental illness)
  • Any patient/carer who does not meet all of the inclusion criteria

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Addenbrooke's Hospital

    Cambridge, Cambridgeshire, CB2 0QQ

Other trials in United Kingdom

About this study

Official title: Phase II Pilot Pragmatic Single-Blinded Fast Track Randomised Controlled Trial of the Breathlessness Intervention Service Versus Standard Care for Patients With Chronic Obstructive Pulmonary Disease

The aim of this study is to test the feasibility of conducting a pragmatic fast track Randomized Controlled Trial (RCT) of the Breathlessness Intervention Service (BIS) versus standard care for patients with COPD and their carers, and to begin testing the effectiveness of the intervention.

Read the detailed description

The aim of the study is to test the feasibility of conducting a pragmatic single-blinded fast track RCT of BIS versus standard care for patients with COPD and their carers and to begin testing the effectiveness of the intervention by: (1) Describing the referral patterns and activity of the service; (2) Describing the experiences and views of the service by people with breathlessness who have been referred to it and the experiences and views of those informally involved in their care; (3) Identifying those aspects of the service which are most useful to people with breathlessness, those informally involved in their care and health care professionals.

The study consists of five components: (1) data relating to referral patterns and service activity; (2) identification of components of the intervention; (3) a pilot pragmatic fast-track randomised controlled trial (RCT) of BIS for COPD patients versus standard care; (4) semi-structured interviews with referrers; (5) in-depth interviews with BIS staff. The RCT is described below.

Although the BIS also receives referrals for patients with cancer and heart failure, COPD patients make up the largest diagnostic group of referrals. The pilot trial therefore focuses on a heterogeneous cohort of COPD/COAD patients.

The investigator will be blinded to the allocation of respondents until week 8. This will be achieved by the investigator conducting the recruitment to the study and collecting baseline measures, but then passing the process of randomisation and reporting of allocation (to the patient and provider) over to a third party (clinical trials' nurses) using a random sequence of opaque envelopes previously generated by a study administrator at King's (independent of the service and the RCT). Subsequent to this, all data will be handled using study identity numbers and group allocation identifiers will only be added at the analysis stage. Outcomes are all self-assessed by patients and carers principally using structured questionnaires but also incorporating a qualitative topic guide prior to randomisation and then again at the end of the fast track group's exposure to BIS and the control group's waiting period for BIS (at both of these measurement points structured questionnaires will be completed prior to the qualitative interview).

Subsequent data collected from the control group once they are in receipt of BIS (after their period on the waiting list when their group allocation was blinded to the investigator) will be treated as before/after data and not RCT data. This will allow the collection of qualitative data at the midpoint of using the service as the investigator will no longer be blinded to their group allocation, nor will she be required to be at this stage.

Measurement points: 'measures' (quantitative and qualitative) will be taken for all respondents (FT and CC) at baseline (t1), prior to randomisation. They will be repeated for the fast-track group (FC) during the intervention (4 weeks post commencement of the intervention (FTt2) - quantitative only) and for control condition group at the same time (CCt2 - quantitative only), and then again after discharge for the fast track group (8 weeks post commencement of intervention (FTt3)). As well as being measured at t1 (randomisation) and t2 (mid-point between randomisation and intervention - quantitative only), the control condition group (CC) will also be measured just prior to the commencement of their intervention (CCt3), repeated during the intervention (4 weeks post commencement of the intervention (CCt4)) and then again after discharge (8 weeks post commencement of intervention (CCt5)). Using this measurement strategy should make it possible to identify whether or not the condition of respondents in the control group deteriorated whilst they awaited their intervention and whether or not this then had an impact on final outcomes for this group.

Measures will be collected by means of audio-taped structured/semi-structured interviews (with respondents' permission). It is proposed that at each measurement point patients and carers are interviewed separately as this found to be important in the pilot study interviews. This will be managed by means of requesting that carers complete any self-complete measures whilst the interview is being conducted with the patient. Interviews with carers will then be conducted on a separate, but temporally close, occasion (e.g. up to 2 days later), at the carer's convenience (e.g. in the evening if required). Careful attention will be paid to the needs of the patient and carer in terms of fatigue.

Determining the sample size for a pilot/exploratory trial of this type is difficult. As no trials have been conducted before with this particular intervention, or for this type of intervention with this patient group (i.e. COPD patients), there is a lack of data (e.g. identification of primary outcome measures and their data) to support the power calculations usually used to estimate the required sample size of a definitive RCT (i.e. the number of participants needed to ensure the study is scientifically sound). In addition, those trials that do exist relating to interventions for patients with COPD (e.g. trials of pulmonary rehabilitation rather than breathlessness intervention services) have focused primarily on physiological outcomes such as clinical measures of breathlessness. However, as a result of our earlier work at the Pre-Clinical phase and Phase I, we became aware of the need to look beyond such physiological measures and consider other outcomes (e.g. distress due to breathlessness, ability to choose to participate in social events).

Thus the pilot/exploratory trial (Phase II) will itself provide vital information to inform the power calculations for a future planned definitive RCT (Phase III). The aims of this current pilot/exploratory trial therefore include testing the intervention (the BIS) but also establishing the feasibility of conducting a definitive RCT by testing the trial method (i.e. the pragmatic fast-track design), randomisation procedures and the identification of appropriate primary outcome measures. It is envisaged that the most likely primary patient outcomes will be 'distress due to breathlessness' and mastery of breathlessness; the most likely primary carer outcome is 'carer distress due to breathlessness'. For both patients and carers 'distress due to breathlessness' will be measured using a Visual Analogue Scale (VAS; 0-10cm); a difference between the baseline and follow up measurements of 1cm on this scale could be regarded as clinically significant for patients with intractable breathlessness. This pilot/exploratory RCT will provide the data to confirm or refute these outcomes, and so enhance the design of future definitive trials.

Based on clinical experience, data published from other studies and case reports (e.g. Corner et al, 1996), and on expert advice, we have made some tentative estimates of the likely changes we may expect the intervention to have. We could expect a change in score of severe distress due to breathlessness of 2.2 (SD 1.8) on a 10 point scale. This difference would be detected, using a Mann Whitney U test, with 11 patients in each group (22 in total), with 80% power and a significance of p=0.05. A change in the proportion of patients with severe or very severe distress due to breathlessness from 90% to 40% would be detected at 80% power and a significance of p<0.05 by 14 patients in each group (28 patients in total). Therefore we will aim to recruit at least 30 (or 28) patients to the trial.

A number of subjective measures, exercise tolerance measures and physiological measures are already collected or recorded by the BIS itself (e.g. VAS, modified BORG, MRC grading of dyspnoea symptoms etc.). These will continue to be collected and will be utilised by both the service and the evaluation. In accordance with the aims of the evaluation, other outcomes to be assessed within the trial will relate to patient and carer satisfaction with the service, patient and carer quality of life, patient and carer anxiety, patient mastery, caregiver burden, patients' breathlessness, patient and carer distress due to breathlessness, aspects of the service most useful to users (patients and carers) and other service use.

Conditions
Dyspnea
Being tested
Breathlessness Intervention Service (BIS), Best supportive care (Standard care)
Keywords
Breathlessness, Dyspnoea, Dyspnea, Palliative care, RCT, Randomised controlled trial, COPD, Chronic respiratory disease
Medical subject headings
Dyspnea, Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Breathlessness Intervention Service (BIS)Behavioural

    Also called BIS

    BIS consists of a clinical specialist physiotherapist \& palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social \& physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); \& pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs \& allied health professionals (with medical consent).

  • Best supportive care (Standard care)Behavioural

    Also called Standard care

    Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.

Study groups in NCT00711438
Study groupRoleWhat they receive
FTExperimentalBreathlessness Intervention Service (BIS)
Receives: Behavioral: Breathlessness Intervention Service (BIS)
WLActive comparatorBest supportive care
Receives: Behavioral: Best supportive care (Standard care)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Visual Analogue Scale (VAS) - distress due to breathlessness

    Measured: End of intervention (8 weeks after baseline)

Secondary outcomes (9)
  1. Modified BORG

    Measured: As for primary outcome measure

  2. VAS breathlessness at best /worst

    Measured: As for primary outcome measure

  3. Mastery scale of CRQ

    Measured: As for primary outcome measure

  4. SEIQoL-DW

    Measured: As for primary outcome measure

  5. HADS

    Measured: As for primary outcome measure

  6. social functioning

    Measured: As for primary outcome measure

  7. WHO Performance scale

    Measured: As for primary outcome measure

  8. experience of breathlessness & expectations / views of BIS

    Measured: As for primary outcome measure

  9. Carer Burden Interview and Caregiver Appraisal Scale

    Measured: As for primary outcome measure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2008 (estimated)
  2. Study startApr 2006
  3. Primary completionApr 2007
  4. Study completionApr 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
13 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00711438
Sponsor's protocol ID
BIS PhIInm v3 26/10/06
Acronym
BIS-PhIInm
Status last verified
Oct 2006
First submitted
3 Jul 2008
Last updated
8 Jul 2008
Results posted
No
Data monitoring committee
No

Publications

  • Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. Palliat Support Care. 2003 Dec;1(4):337-44. doi: 10.1017/s1478951503030499.

    PubMed 16594223
  • Booth S, Farquhar M, Gysels M, Bausewein C, Higginson IJ. The impact of a breathlessness intervention service (BIS) on the lives of patients with intractable dyspnea: a qualitative phase 1 study. Palliat Support Care. 2006 Sep;4(3):287-93. doi: 10.1017/s1478951506060366.

    PubMed 17066970
  • Booth S, Wade R. Oxygen or air for palliation of breathlessness in advanced cancer. J R Soc Med. 2003 May;96(5):215-8. doi: 10.1177/014107680309600503. No abstract available.

    PubMed 12724429
  • Booth S, Adams L. The shuttle walking test: a reproducible method for evaluating the impact of shortness of breath on functional capacity in patients with advanced cancer. Thorax. 2001 Feb;56(2):146-50. doi: 10.1136/thorax.56.2.146.

    PubMed 11209105
  • Booth S. The management of dyspnoea in advanced cancer. Hosp Med. 1998 May;59(5):348-9. No abstract available.

    PubMed 9722382
  • Bausewein C, Farquhar M, Booth S, Gysels M, Higginson IJ. Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2007 Mar;101(3):399-410. doi: 10.1016/j.rmed.2006.07.003. Epub 2006 Aug 17.

    PubMed 16914301
  • Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005623. doi: 10.1002/14651858.CD005623.pub2.

    PubMed 18425927
  • Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H; Expert Working Group of the Scientific Committee of the Association of Palliative Medicine. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respir Med. 2004 Jan;98(1):66-77. doi: 10.1016/j.rmed.2003.08.008.

    PubMed 14959816
  • Farquhar MC, Higginson IJ, Fagan P, Booth S. The feasibility of a single-blinded fast-track pragmatic randomised controlled trial of a complex intervention for breathlessness in advanced disease. BMC Palliat Care. 2009 Jul 7;8:9. doi: 10.1186/1472-684X-8-9.

    PubMed 19583857

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Breathlessness Intervention Service (BIS) in people with Dyspnea, run by Cambridge University Hospitals NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jul 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Visual Analogue Scale (VAS) - distress due to breathlessness (time frame: End of intervention (8 weeks after baseline)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00711438, which also lists 9 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2008.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in